It is only prescribed for about 12 weeks
The impending loss of exclusivity for semaglutide, the active ingredient in Ozempic and Wegovy, in 2026 is poised to transform the anti-obesity medication (AOM) market, particularly in countries like India, China, Canada, Brazil, and Turkey, which represent 40% of the global population and 33% of adults with obesity
Patients with certain genetic profiles show higher sensitivity to GLP-1 effects, meaning they reach therapeutic results at lower doses and suffer more severe side effects if over-dosed
Indeed, BPC-157 is having a moment
View Abstract [15] de Souza-Pinto NC, Eide L, Hogue BA, Thybo T, Stevnsner T, Seeberg E, Klungland A, Bohr VA
Every FDA Warning Letter offers more than a glimpse into individual noncompliance